-
公开(公告)号：US5452138A
公开(公告)日：1995-09-19
申请号：US68019
申请日：1993-05-27
CPC分类号： G09F9/372
摘要： A deformable mirror device comprises a plurality of groups of colored mirrors responsive to electronic signals. Each group of mirrors is coated with a mixture of resist and dye thereby reflecting specified wavelengths of visible light.
摘要翻译： 可变形反射镜装置包括响应于电子信号的多组有色反射镜。 每组镜子都涂上抗蚀剂和染料的混合物，从而反射出特定波长的可见光。
-
2.发明授权
公开(公告)号：US5240818A
公开(公告)日：1993-08-31
申请号：US739079
申请日：1991-07-31
CPC分类号： G09F9/372
摘要： A deformable mirror device comprises a plurality of groups of colored mirrors responsive to electronic signals. Each group of mirrors is coated with a mixture of resist and dye thereby reflecting specified wavelengths of visible light. A process for manufacturing such a color deformable mirror device ("DMD") includes forming a layer of material on the DMD comprising a resist and a dye and selectively removing portions of the layer of material from the DMD.
-
公开(公告)号：US08623839B2
公开(公告)日：2014-01-07
申请号：US13173658
申请日：2011-06-30
申请人： Dongling Su , Julia Hwang , Brooks J. Story
发明人： Dongling Su , Julia Hwang , Brooks J. Story
IPC分类号： A61K31/728 , A61K31/7004 , A61K47/26 , A61K9/19 , A61P29/00
CPC分类号： A61K47/26 , A61K9/0019 , A61K9/19 , A61K31/726 , A61K31/728 , A61K31/737 , A61K47/02 , A61K47/10 , A61K2300/00
摘要： Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans (“GAG”) or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (“CS”), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (“GlcN”).
摘要翻译： 提供组合物和方法用于治疗关节病，例如骨关节炎和/或与之相关的疼痛。 组合物和方法利用第一组分，即透明质酸（“HA”）与至少一种稳定剂的组合。 组合物可以包括增加HA的稳定性和保质期的稳定剂。 在另一个实施方案中，组合物和方法还可以包括另外的组分，例如一种或多种糖胺聚糖（“GAG”）或GAG前体。 GAG或GAG前体的实例可以包括硫酸软骨素（“CS”），硫酸皮肤素，肝素，硫酸乙酰肝素，硫酸角质素和葡糖胺（“GlcN”）。
-
公开(公告)号：US08592201B2
公开(公告)日：2013-11-26
申请号：US13567322
申请日：2012-08-06
CPC分类号： A61M31/002 , A61K9/0024 , A61K35/32 , A61L27/3817 , A61L27/54 , A61L2300/602 , A61M5/00 , A61M5/142 , A61M5/145 , A61M5/1452 , A61M39/22 , C12N5/0655 , C12N2533/76
摘要： Devices and methods for delivering a therapeutic agent produced via a genetically-altered chondrocyte are provided. More specifically, the device includes a housing which defines a cell chamber configured to retain a large volume of chondrocytes while selectively releasing therapeutic agents produced via these entrapped cells. In an exemplary embodiment, the cell chamber can be configured such that a portion of cells can be positioned at least about 1.5 mm from an external wall of the device (i.e., about 1.5 mm away from an external nutrient supply). For example, the cell chamber can have a tubular configuration having a length and a diameter wherein each of these dimensions is at least about 3 mm (thereby the central core to the chamber is at least about 1.5 mm from the outer wall of the device).
摘要翻译： 提供用于递送通过遗传改变的软骨细胞产生的治疗剂的装置和方法。 更具体地，该装置包括壳体，其限定被配置为保持大体积的软骨细胞的细胞室，同时选择性地释放通过这些被捕获的细胞产生的治疗剂。 在一个示例性实施例中，细胞室可以被配置成使得细胞的一部分可以位于与装置的外壁至少约1.5mm（即离开外部营养物质约1.5mm）处。 例如，电池室可以具有长度和直径的管状构造，其中这些尺寸中的每个尺寸至少为约3mm（由此到室的中心芯离开装置的外壁至少约1.5mm） 。
-
公开(公告)号：US08153117B2
公开(公告)日：2012-04-10
申请号：US11463714
申请日：2006-08-10
申请人： Francois Binette , Brooks J. Story
发明人： Francois Binette , Brooks J. Story
CPC分类号： C12N5/0655 , A61K35/12 , C12N2510/00 , C12N2533/74 , C12N2533/76
摘要： Methods and compositions for producing therapeutic agents using chondrocytes are provided. The genetically engineered chondrocytes can be used to express the therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.
摘要翻译： 提供了使用软骨细胞产生治疗剂的方法和组合物。 基因工程软骨细胞可用于在受试者中表达治疗剂，包括在通常与软骨细胞相关的环境中以及通常不与软骨细胞相关的环境中。
-
6.发明授权公开(公告)号：US06193516B1
公开(公告)日：2001-02-27
申请号：US09336322
申请日：1999-06-18
申请人： Brooks J. Story
发明人： Brooks J. Story
IPC分类号： A61C800
CPC分类号： A61C8/0086
摘要： A dental implant that reduces the potential for stress shielding. The dental implant utilizes an implant body that includes a metallic core and a shell disposed about the metallic core. The shell is made from a material that has a lower modulus of elasticity than the metallic core. The metallic core also is connected to a mounting end to which a prosthetic tooth may ultimately be attached.
摘要翻译： 减少应力屏蔽潜力的牙科植入物。 牙科植入物利用包括金属芯和围绕金属芯设置的外壳的植入体。 壳体由具有比金属芯体更低的弹性模量的材料制成。 金属芯也连接到可以最终附接假牙的安装端。
-
公开(公告)号：US08394369B2
公开(公告)日：2013-03-12
申请号：US11463708
申请日：2006-08-10
申请人： Francois Binette , Brooks J. Story
发明人： Francois Binette , Brooks J. Story
CPC分类号： C12N5/0655 , A61K35/12 , C12N2510/00 , C12N2533/74 , C12N2533/76
摘要： Methods and compositions for producing therapeutic agents using chondrocytes are provided. The genetically engineered chondrocytes can be used to express the therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.
摘要翻译： 提供了使用软骨细胞产生治疗剂的方法和组合物。 基因工程软骨细胞可用于在受试者中表达治疗剂，包括在通常与软骨细胞相关的环境中以及通常不与软骨细胞相关的环境中。
-
公开(公告)号：US08354100B2
公开(公告)日：2013-01-15
申请号：US13069543
申请日：2011-03-23
CPC分类号： A61K35/32 , A61K9/0024 , A61K35/12 , A61L27/3817 , A61L27/54 , A61L2300/252 , A61L2430/02 , A61L2430/06 , C12N5/0655 , C12N2510/00 , C12N2533/74 , C12N2533/76
摘要： Systems and methods for modifying the environment of target cell using genetically altered chondrocytes are provided. The genetically engineered chondrocytes can be used to express a therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.
-
公开(公告)号：US20130005681A1
公开(公告)日：2013-01-03
申请号：US13173658
申请日：2011-06-30
申请人： Dongling Su , Julia Hwang , Brooks J. Story
发明人： Dongling Su , Julia Hwang , Brooks J. Story
IPC分类号： A61K31/728 , A61P29/00 , A61P19/04 , A61P19/02
CPC分类号： A61K47/26 , A61K9/0019 , A61K9/19 , A61K31/726 , A61K31/728 , A61K31/737 , A61K47/02 , A61K47/10 , A61K2300/00
摘要： Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans (“GAG”) or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (“CS”), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (“GlcN”).
摘要翻译： 提供组合物和方法用于治疗关节病，例如骨关节炎和/或与之相关的疼痛。 组合物和方法利用第一组分，即透明质酸（HA）与至少一种稳定剂的组合。 组合物可以包括增加HA的稳定性和保质期的稳定剂。 在另一个实施方案中，组合物和方法还可以包括另外的组分，例如一种或多种糖胺聚糖（GAG）或GAG前体。 GAG或GAG前体的实例可包括硫酸软骨素（CS），硫酸皮肤素，肝素，硫酸乙酰肝素，硫酸角质素和葡糖胺（GlcN）。
-
公开(公告)号：US20080181954A1
公开(公告)日：2008-07-31
申请号：US11463708
申请日：2006-08-10
申请人： Francois Binette , Brooks J. Story
发明人： Francois Binette , Brooks J. Story
CPC分类号： C12N5/0655 , A61K35/12 , C12N2510/00 , C12N2533/74 , C12N2533/76
摘要： Methods and compositions for producing therapeutic agents using chondrocytes are provided. The genetically engineered chondrocytes can be used to express the therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.
摘要翻译： 提供了使用软骨细胞产生治疗剂的方法和组合物。 基因工程软骨细胞可用于在受试者中表达治疗剂，包括在通常与软骨细胞相关的环境中以及通常不与软骨细胞相关的环境中。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.023 秒)
